Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial
We explored viral and symptom rebound after COVID-19 amubarvimab/romlusevimab monoclonal antibody therapy vs placebo in the randomized ACTIV-2/A5401 trial. Participants underwent nasal SARS-CoV-2 PCR at study days 3, 7, 14, and 28. Viral rebound was defined as RNA ≥3 and ≥0.5 log10 copies/mL increas...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2024-10 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | The Journal of infectious diseases |
| container_volume | |
| creator | Chew, Kara W McGinley, Brooke Moser, Carlee Li, Jonathan Z Evering, Teresa H Ritz, Justin Javan, Arzhang Cyrus Margolis, David Wohl, David A Hughes, Michael D Daar, Eric S Currier, Judith S Eron, Joseph J Smith, Davey M |
| description | We explored viral and symptom rebound after COVID-19 amubarvimab/romlusevimab monoclonal antibody therapy vs placebo in the randomized ACTIV-2/A5401 trial. Participants underwent nasal SARS-CoV-2 PCR at study days 3, 7, 14, and 28. Viral rebound was defined as RNA ≥3 and ≥0.5 log10 copies/mL increase from day 3 or 7, and symptom rebound as hospitalization or any moderate/severe symptom for ≥2 days after initial symptom improvement. There was no difference in viral rebound (∼5%/arm) (analysis population n=713) or symptom rebound among participants who initially improved (hazard ratio 0.95 (95% CI 0.52, 1.75, analysis population) n=574); |
| doi_str_mv | 10.1093/infdis/jiae501 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_3116338758</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3116338758</sourcerecordid><originalsourceid>FETCH-LOGICAL-p563-c7a0544bc727fdf601e320de203e01fa72dcfaf929b0101e0a29056f4133da103</originalsourceid><addsrcrecordid>eNpNkM9LwzAUx4Mobk6vHiVHL3FJX5uuxzH8BYLgxq4lbRLNSJOadGj96w06wdN73x_vc3gIXTJ6w2gFc-O0NHG-M0IVlB2hKSugJJwzOP63T9BZjDtKaQ68PEUTqPIkOEzR59YEYbFwEsex6wff4aAav09ae2v9h3GvKR0MWS9f1mTltyTDnXe-td79HA6m8XLEw5sKoh-xcVjgkHi-M19K4t6KNgFJ690QEjFZQzDCnqMTLWxUF4c5Q5u7283qgTw93z-ulk-kLziQthS0yPOmLbNSS80pU5BRqTIKijItyky2WugqqxrKUkhFVtGC65wBSMEozND1L7YP_n2v4lB3JrbKWuGU38caGOMAi7JYpOrVobpvOiXrPphOhLH-exZ8A8f9blE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3116338758</pqid></control><display><type>article</type><title>Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Chew, Kara W ; McGinley, Brooke ; Moser, Carlee ; Li, Jonathan Z ; Evering, Teresa H ; Ritz, Justin ; Javan, Arzhang Cyrus ; Margolis, David ; Wohl, David A ; Hughes, Michael D ; Daar, Eric S ; Currier, Judith S ; Eron, Joseph J ; Smith, Davey M</creator><creatorcontrib>Chew, Kara W ; McGinley, Brooke ; Moser, Carlee ; Li, Jonathan Z ; Evering, Teresa H ; Ritz, Justin ; Javan, Arzhang Cyrus ; Margolis, David ; Wohl, David A ; Hughes, Michael D ; Daar, Eric S ; Currier, Judith S ; Eron, Joseph J ; Smith, Davey M ; ACTIV-2/A5401 Study Team</creatorcontrib><description>We explored viral and symptom rebound after COVID-19 amubarvimab/romlusevimab monoclonal antibody therapy vs placebo in the randomized ACTIV-2/A5401 trial. Participants underwent nasal SARS-CoV-2 PCR at study days 3, 7, 14, and 28. Viral rebound was defined as RNA ≥3 and ≥0.5 log10 copies/mL increase from day 3 or 7, and symptom rebound as hospitalization or any moderate/severe symptom for ≥2 days after initial symptom improvement. There was no difference in viral rebound (∼5%/arm) (analysis population n=713) or symptom rebound among participants who initially improved (hazard ratio 0.95 (95% CI 0.52, 1.75, analysis population) n=574); <1% had both viral/symptom rebound.</description><identifier>ISSN: 1537-6613</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jiae501</identifier><identifier>PMID: 39400063</identifier><language>eng</language><publisher>United States</publisher><ispartof>The Journal of infectious diseases, 2024-10</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-7764-0212 ; 0000-0001-9914-9662 ; 0000-0003-4865-4348 ; 0000-0001-5601-9112 ; 0000-0001-9717-6165 ; 0000-0002-4938-0644</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39400063$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chew, Kara W</creatorcontrib><creatorcontrib>McGinley, Brooke</creatorcontrib><creatorcontrib>Moser, Carlee</creatorcontrib><creatorcontrib>Li, Jonathan Z</creatorcontrib><creatorcontrib>Evering, Teresa H</creatorcontrib><creatorcontrib>Ritz, Justin</creatorcontrib><creatorcontrib>Javan, Arzhang Cyrus</creatorcontrib><creatorcontrib>Margolis, David</creatorcontrib><creatorcontrib>Wohl, David A</creatorcontrib><creatorcontrib>Hughes, Michael D</creatorcontrib><creatorcontrib>Daar, Eric S</creatorcontrib><creatorcontrib>Currier, Judith S</creatorcontrib><creatorcontrib>Eron, Joseph J</creatorcontrib><creatorcontrib>Smith, Davey M</creatorcontrib><creatorcontrib>ACTIV-2/A5401 Study Team</creatorcontrib><title>Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>We explored viral and symptom rebound after COVID-19 amubarvimab/romlusevimab monoclonal antibody therapy vs placebo in the randomized ACTIV-2/A5401 trial. Participants underwent nasal SARS-CoV-2 PCR at study days 3, 7, 14, and 28. Viral rebound was defined as RNA ≥3 and ≥0.5 log10 copies/mL increase from day 3 or 7, and symptom rebound as hospitalization or any moderate/severe symptom for ≥2 days after initial symptom improvement. There was no difference in viral rebound (∼5%/arm) (analysis population n=713) or symptom rebound among participants who initially improved (hazard ratio 0.95 (95% CI 0.52, 1.75, analysis population) n=574); <1% had both viral/symptom rebound.</description><issn>1537-6613</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNkM9LwzAUx4Mobk6vHiVHL3FJX5uuxzH8BYLgxq4lbRLNSJOadGj96w06wdN73x_vc3gIXTJ6w2gFc-O0NHG-M0IVlB2hKSugJJwzOP63T9BZjDtKaQ68PEUTqPIkOEzR59YEYbFwEsex6wff4aAav09ae2v9h3GvKR0MWS9f1mTltyTDnXe-td79HA6m8XLEw5sKoh-xcVjgkHi-M19K4t6KNgFJ690QEjFZQzDCnqMTLWxUF4c5Q5u7283qgTw93z-ulk-kLziQthS0yPOmLbNSS80pU5BRqTIKijItyky2WugqqxrKUkhFVtGC65wBSMEozND1L7YP_n2v4lB3JrbKWuGU38caGOMAi7JYpOrVobpvOiXrPphOhLH-exZ8A8f9blE</recordid><startdate>20241014</startdate><enddate>20241014</enddate><creator>Chew, Kara W</creator><creator>McGinley, Brooke</creator><creator>Moser, Carlee</creator><creator>Li, Jonathan Z</creator><creator>Evering, Teresa H</creator><creator>Ritz, Justin</creator><creator>Javan, Arzhang Cyrus</creator><creator>Margolis, David</creator><creator>Wohl, David A</creator><creator>Hughes, Michael D</creator><creator>Daar, Eric S</creator><creator>Currier, Judith S</creator><creator>Eron, Joseph J</creator><creator>Smith, Davey M</creator><scope>NPM</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7764-0212</orcidid><orcidid>https://orcid.org/0000-0001-9914-9662</orcidid><orcidid>https://orcid.org/0000-0003-4865-4348</orcidid><orcidid>https://orcid.org/0000-0001-5601-9112</orcidid><orcidid>https://orcid.org/0000-0001-9717-6165</orcidid><orcidid>https://orcid.org/0000-0002-4938-0644</orcidid></search><sort><creationdate>20241014</creationdate><title>Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial</title><author>Chew, Kara W ; McGinley, Brooke ; Moser, Carlee ; Li, Jonathan Z ; Evering, Teresa H ; Ritz, Justin ; Javan, Arzhang Cyrus ; Margolis, David ; Wohl, David A ; Hughes, Michael D ; Daar, Eric S ; Currier, Judith S ; Eron, Joseph J ; Smith, Davey M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p563-c7a0544bc727fdf601e320de203e01fa72dcfaf929b0101e0a29056f4133da103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chew, Kara W</creatorcontrib><creatorcontrib>McGinley, Brooke</creatorcontrib><creatorcontrib>Moser, Carlee</creatorcontrib><creatorcontrib>Li, Jonathan Z</creatorcontrib><creatorcontrib>Evering, Teresa H</creatorcontrib><creatorcontrib>Ritz, Justin</creatorcontrib><creatorcontrib>Javan, Arzhang Cyrus</creatorcontrib><creatorcontrib>Margolis, David</creatorcontrib><creatorcontrib>Wohl, David A</creatorcontrib><creatorcontrib>Hughes, Michael D</creatorcontrib><creatorcontrib>Daar, Eric S</creatorcontrib><creatorcontrib>Currier, Judith S</creatorcontrib><creatorcontrib>Eron, Joseph J</creatorcontrib><creatorcontrib>Smith, Davey M</creatorcontrib><creatorcontrib>ACTIV-2/A5401 Study Team</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chew, Kara W</au><au>McGinley, Brooke</au><au>Moser, Carlee</au><au>Li, Jonathan Z</au><au>Evering, Teresa H</au><au>Ritz, Justin</au><au>Javan, Arzhang Cyrus</au><au>Margolis, David</au><au>Wohl, David A</au><au>Hughes, Michael D</au><au>Daar, Eric S</au><au>Currier, Judith S</au><au>Eron, Joseph J</au><au>Smith, Davey M</au><aucorp>ACTIV-2/A5401 Study Team</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2024-10-14</date><risdate>2024</risdate><issn>1537-6613</issn><eissn>1537-6613</eissn><abstract>We explored viral and symptom rebound after COVID-19 amubarvimab/romlusevimab monoclonal antibody therapy vs placebo in the randomized ACTIV-2/A5401 trial. Participants underwent nasal SARS-CoV-2 PCR at study days 3, 7, 14, and 28. Viral rebound was defined as RNA ≥3 and ≥0.5 log10 copies/mL increase from day 3 or 7, and symptom rebound as hospitalization or any moderate/severe symptom for ≥2 days after initial symptom improvement. There was no difference in viral rebound (∼5%/arm) (analysis population n=713) or symptom rebound among participants who initially improved (hazard ratio 0.95 (95% CI 0.52, 1.75, analysis population) n=574); <1% had both viral/symptom rebound.</abstract><cop>United States</cop><pmid>39400063</pmid><doi>10.1093/infdis/jiae501</doi><orcidid>https://orcid.org/0000-0002-7764-0212</orcidid><orcidid>https://orcid.org/0000-0001-9914-9662</orcidid><orcidid>https://orcid.org/0000-0003-4865-4348</orcidid><orcidid>https://orcid.org/0000-0001-5601-9112</orcidid><orcidid>https://orcid.org/0000-0001-9717-6165</orcidid><orcidid>https://orcid.org/0000-0002-4938-0644</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1537-6613 |
| ispartof | The Journal of infectious diseases, 2024-10 |
| issn | 1537-6613 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3116338758 |
| source | Oxford University Press Journals All Titles (1996-Current) |
| title | Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A47%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Viral%20and%20symptom%20rebound%20following%20anti-SARS-CoV-2%20monoclonal%20antibody%20therapy%20in%20a%20randomized%20placebo-controlled%20trial&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Chew,%20Kara%20W&rft.aucorp=ACTIV-2/A5401%20Study%20Team&rft.date=2024-10-14&rft.issn=1537-6613&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jiae501&rft_dat=%3Cproquest_pubme%3E3116338758%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3116338758&rft_id=info:pmid/39400063&rfr_iscdi=true |